-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30, 2021, Visus Therapeutics announced that a phase 2 clinical trial evaluating the efficacy of the innovative eye drops Brimochol under development has achieved positive results
Presbyopia is a common vision loss that occurs with age, affecting billions of people worldwide
Visus' research product, Brimochol, is an eye drop designed to be administered once a day to correct near vision loss associated with presbyopia
A total of 85 patients with presbyopia between the ages of 45-80 were enrolled in this dose-exploring, multi-center, three-arm phase 3 clinical trial
The results of the test showed that in the three treatment groups, at least 83% of the subjects had an increase in DCNVA, which is an index for detecting near vision, by at least 3 lines within 1 hour of treatment, and a decrease in distance vision index by less than 1 line
Reference materials:
[1] Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopia.